Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2021 Publisher: Glaxo Wellcome UK Ltd trading as Glaxo Laboratories and/or GlaxoSmithKline UK, 980 Great West Road, Brentford, Middlesex, TW8 9GS
Dermovate Scalp Application.
Pharmaceutical Form |
---|
Scalp application. |
Each 1 g contains 0.5 mg of clobetasol propionate (0.05% w/w).
Active Ingredient | Description | |
---|---|---|
Clobetasol propionate |
Clobetasol propionate, like other topical corticosteroids, has anti-inflammatory, antipruritic, and vasoconstrictive properties. Corticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor arachidonic acid. |
List of Excipients |
---|
Carbomer |
White High Density Polyethylene (HDPE) container with a white low density polyethylene (LDPE) nozzle and a white HDPE screw cap.
Pack size: 25ml, 30ml, 100ml.
Not all pack sizes may be marketed.
Glaxo Wellcome UK Ltd trading as Glaxo Laboratories and/or GlaxoSmithKline UK, 980 Great West Road, Brentford, Middlesex, TW8 9GS
PL 10949/0046
Date of first authorisation: 01 April 1993
Date of last renewal: 24 February 2010
Drug | Countries | |
---|---|---|
DERMOVATE | Austria, Canada, Cyprus, Germany, Ecuador, Estonia, Hong Kong, Ireland, Israel, Japan, Lithuania, Malta, Nigeria, Netherlands, Poland, Romania, Singapore, Turkey, United Kingdom, South Africa |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.